Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel
NASDAQ:INGN

Inogen Q2 2026 Earnings Report

Inogen logo
$6.54 +0.01 (+0.15%)
Closing price 07/10/2026 04:00 PM Eastern
Extended Trading
$6.54 +0.00 (+0.08%)
As of 07/10/2026 06:02 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

Inogen EPS Results

Actual EPS
N/A
Consensus EPS
-$0.17
Beat/Miss
N/A
One Year Ago EPS
N/A

Inogen Revenue Results

Actual Revenue
N/A
Expected Revenue
$95.23 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Inogen Announcement Details

Quarter
Q2 2026
Date
8/6/2026
Time
Before Market Opens
Conference Call Date
Thursday, August 6, 2026
Conference Call Time
5:00PM ET

Conference Call Resources

Inogen Earnings Headlines

Inogen Appoints New Chief Operating Officer for Growth
July 9 at 8:09 AM  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/INGN-Q/pressreleases/3106716/inogen-appoints-new-chief-operating-officer-for-growth/
Inogen (NASDAQ:INGN) EVP Boyer Jennifer Yi Sells 10,938 Shares of Stock
July 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30884741
Do NOT Buy SpaceX – Do This Instead
SpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.tc pixel
July 11 at 1:00 AM  |  Stansberry Research (Ad)
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
July 1, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260701409894/en/inogen-announces-the-appointment-of-andy-reding-as-chief-operating-officer/
Inogen Shareholders Approve Expanded Equity Incentive Plan
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inogen-shareholders-approve-expanded-equity-incentive-plan?utm_source=marketbeat.com&utm_medium=referral
Inogen Earnings Call: International Strength Amid U.S. Strain
May 20, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/inogen-earnings-call-international-strength-amid-u-s-strain?utm_source=marketbeat.com&utm_medium=referral
See More Inogen Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Inogen? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Inogen and other key companies, straight to your email.

About Inogen

Inogen (NASDAQ:INGN). (NASDAQ: INGN) is a medical device company specializing in the development, manufacture and marketing of innovative oxygen therapy solutions. The company’s core focus is on portable oxygen concentrators (POCs) designed to support patients with chronic respiratory conditions such as chronic obstructive pulmonary disease (COPD). Inogen’s offerings aim to provide users with mobility and independence by reducing reliance on traditional compressed-gas cylinders and enabling oxygen therapy on the go.

Inogen’s flagship product line, including the Inogen One family of portable oxygen concentrators, leverages proprietary flow technology to deliver continuous and pulse-dose oxygen. These devices are engineered to be lightweight, battery-powered and FAA-approved for in-flight use, addressing both clinical efficacy and user convenience. The company also offers supporting accessories such as batteries, chargers and carrying cases to enhance patient experience and ensure uninterrupted oxygen delivery.

Founded in 2001 and headquartered in Goleta, California, Inogen has obtained regulatory clearance from the U.S. Food and Drug Administration (FDA) and CE Mark approval for distribution in Europe. The company serves a global customer base through direct-to-consumer sales channels as well as partnerships with home healthcare providers and distributors across North America, Europe and parts of the Asia-Pacific region. Inogen is led by President and Chief Executive Officer Scott Wilkinson, under whose leadership the company has invested in research and development to expand its product portfolio and support emerging digital health initiatives.

View Inogen Profile
Earnings Tools